As of 2024-12-13, the EV/EBITDA ratio of Vanda Pharmaceuticals Inc (VNDA) is -40.17. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VNDA's latest enterprise value is 168.90 mil USD. VNDA's TTM EBITDA according to its financial statements is -4.20 mil USD. Dividing these 2 quantities gives us the above VNDA EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 13.6x - 16.6x | 14.9x |
| Forward P/E multiples | 15.5x - 22.4x | 18.2x |
| Fair Price | 0.74 - 4.85 | 2.46 |
| Upside | -83.9% - 5.1% | -46.8% |
| Date | EV/EBITDA |
| 2024-12-11 | -40.86 |
| 2024-12-10 | -39.89 |
| 2024-12-09 | -42.94 |
| 2024-12-06 | -43.22 |
| 2024-12-05 | -42.38 |
| 2024-12-04 | -43.22 |
| 2024-12-03 | -44.19 |
| 2024-12-02 | -45.99 |
| 2024-11-29 | -47.51 |
| 2024-11-27 | -48.07 |
| 2024-11-26 | -45.16 |
| 2024-11-25 | -46.13 |
| 2024-11-22 | -46.68 |
| 2024-11-21 | -44.60 |
| 2024-11-20 | -44.05 |
| 2024-11-19 | -44.33 |
| 2024-11-18 | -45.16 |
| 2024-11-15 | -45.43 |
| 2024-11-14 | -46.82 |
| 2024-11-13 | -51.81 |
| 2024-11-12 | -50.98 |
| 2024-11-11 | -50.15 |
| 2024-11-08 | -48.07 |
| 2024-11-07 | -45.71 |
| 2024-11-06 | -43.91 |
| 2024-11-05 | -42.52 |
| 2024-11-04 | -43.35 |
| 2024-11-01 | -40.72 |
| 2024-10-31 | -40.58 |
| 2024-10-30 | -39.33 |
| 2024-10-29 | -41.14 |
| 2024-10-28 | -42.38 |
| 2024-10-25 | -39.19 |
| 2024-10-24 | -38.78 |
| 2024-10-23 | -41.14 |
| 2024-10-22 | -41.69 |
| 2024-10-21 | -41.69 |
| 2024-10-18 | -44.19 |
| 2024-10-17 | -41.76 |
| 2024-10-16 | -44.05 |
| 2024-10-15 | -42.66 |
| 2024-10-14 | -42.80 |
| 2024-10-11 | -37.67 |
| 2024-10-10 | -37.25 |
| 2024-10-09 | -38.09 |
| 2024-10-08 | -38.36 |
| 2024-10-07 | -38.50 |
| 2024-10-04 | -40.30 |
| 2024-10-03 | -38.50 |
| 2024-10-02 | -39.75 |